NEFL and myeloid sarcoma: NfL has been reported to be an important candidate biomarker in diseases such as MS [22], NMOSD [23], Alzheimer’s disease, frontotemporal dementia, amyotrophic lateral sclerosis, Huntington’s disease, atypical Parkinson’s disease and traumatic brain injury [24,25].